A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes

Table 9 Impact of differences in EQ-5D index scores using UK, US, and Japan preference weights on ICUR for 7 hypothetical decision trees

Variables	Hypothetical decision tree
	1	2	3	4	5	6	7
EQ-5D index scores when the drug was effective (success)
Drug A	0.900	0.951	0.916	0.967	0.935	0.928	0.981
Drug B	0.800	0.851	0.816	0.867	0.835	0.828	0.881
EQ-5D index scores when the drug was not effective (failure)
Drug A	0.500	0.551	0.516	0.567	0.535	0.528	0.581
Drug B	0.400	0.451	0.416	0.467	0.435	0.428	0.481
QALY
Drug A	6.40	6.81	6.53	6.94	6.68	6.62	7.05
Drug B	4.00	4.31	4.10	4.40	4.21	4.17	4.49
Incremental cost (Baht)	300,000	300,000	300,000	300,000	300,000	300,000	300,000
Incremental QALY	2.40	2.50	2.43	2.54	2.47	2.45	2.56
ICUR (Baht/QALY)	125,000	119,904	123,457	118,110	121,457	122,150	117,096
% Difference in ICUR from base case (Decision tree 1)	-	4.08	1.23	5.51	2.83	2.28	6.32

Decision tree 1 represents the base-case scenario, while decision trees 2–7 mean the scenarios where base-case utility scores overestimated by 0.051 (mean difference between UK versus US weights), 0.016 (mean difference between UK versus Japan weights), 0.067 (mean difference between US versus Japan weights), 0.035 (median difference between UK versus US weights), 0.028 (median difference between UK versus Japan weights), and 0.081 (median difference between US versus Japan weights).

ISSN: 1477-7525